Table 1.

Characteristics of engineered T cell trials that have demonstrated clinical activity in solid cancers^a

Antigen-targeting receptor	Conditioning regimen	Maximum cell dose	Transduction efficiency (median/range)	Systemic cytokine therapy	Tumor responses (responses/N)
MART1 TCR52	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	107 × 109	71	Aldesleukin 720,000 IU/kg q8hrs	6/20
gp100 TCR52	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	110 × 109	82	Aldesleukin 720,000 IU/kg q8hrs	3/16
NY-ESO-1 TCR50	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	130 × 109	78, 62b	Aldesleukin 720,000 IU/kg q8hrs	22/38
NY-ESO-1 TCR57	Cyclophosphamide 1,800 mg/m2 × 2 days Fludarabine 30 mg/m2 × 4 days	14 × 109	N/Ac	None	6/12
NY-ESO-1 TCR58	Cyclophosphamide 600–1,800 mg/m2 × 2–3 days Fludarabine 30 mg/m2 × 3–4 days	N/Ac	N/Ac	None	9/30
MAGE-A3 TCR43	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	120 × 109	90	Aldesleukin 720,000 IU/kg q8hrs	4/17
MAGE-A3/A9/A12 TCR64	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	79 × 109	85	Aldesleukin 720,000 IU/kg q8hrs	5/9
E6 TCR9	Cyclophosphamide 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	134 × 109	60	Aldesleukin 720,000 IU/kg q8hrs	2/12
E7 TCR8	Cyclophosphamide 30 or 60 mg/kg × 2 days Fludarabine 25 mg/m2 × 5 days	120 × 109	96	Aldesleukin 720,000 IU/kg q8hrs	6/12
CLDN18.2 CAR10	Cyclophosphamide 250 mg/m2 × 3 days Fludarabine 25 mg/m2 × 2 days Nab-paclitaxel 100 mg or Gemcitabine 1,000 mg × 1 day	5 × 108	N/Ac	None	18/37

^aClinical trials with ≥2 objective responses by RECIST criteria.

^bCD8⁺ and CD4⁺ T cells, respectively.

^cNot available.